Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2024 08:30 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces Refocusing of Sanofi Collaboration

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
April 10, 2024 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
March 07, 2024 16:10 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
February 01, 2024 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
January 03, 2024 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
December 05, 2023 16:01 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All...
November 13, 2023 16:10 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces Third Quarter 2023 Financial Results

– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM...
November 07, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
October 03, 2023 16:05 ET | Source: IGM Biosciences, Inc.

IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors

MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
September 06, 2023 07:00 ET | Source: IGM Biosciences, Inc.

IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

MOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...